<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Reprod Biol Endocrinol</journal-id><journal-title>Reproductive Biology and Endocrinology : RB&#x00026;E</journal-title><issn pub-type="epub">1477-7827</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1477-7827-7-77</article-id><article-id pub-id-type="pmid">19627578</article-id><article-id pub-id-type="doi">10.1186/1477-7827-7-77</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Ovarian steroids regulate tachykinin and tachykinin receptor gene expression in the mouse uterus</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Pinto</surname><given-names>Francisco M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Francisco.pinto@iiq.csic.es</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Pintado</surname><given-names>C Oscar</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>oscarpintado@us.es</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Pennefather</surname><given-names>Jocelyn N</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jocelyn.oneil@pharm.monash.edu.au</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Patak</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Eva.Patak@med.monash.edu.au</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Candenas</surname><given-names>Luz</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>luzcandenas@iiq.csic.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Instituto de Investigaciones Qu&#x000ed;micas, CSIC, Avda. Americo Vespucio 49, 41092, Sevilla, Spain</aff><aff id="I2"><label>2</label>Centro de Producci&#x000f3;n y Experimentaci&#x000f3;n Animal, Universidad de Sevilla, Sevilla, Spain</aff><aff id="I3"><label>3</label>Department of Pharmaceutical Biology, Monash University, Parkville, Victoria 3052, Australia</aff><aff id="I4"><label>4</label>Department of Anaesthetics, Royal Women's Hospital, Carlton, Victoria 3051, Australia</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>23</day><month>7</month><year>2009</year></pub-date><volume>7</volume><fpage>77</fpage><lpage>77</lpage><ext-link ext-link-type="uri" xlink:href="http://www.rbej.com/content/7/1/77"/><history><date date-type="received"><day>6</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Pinto et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Pinto et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Pinto M Francisco Francisco.pinto@iiq.csic.es </dc:author><dc:title> Ovarian steroids regulate tachykinin and tachykinin receptor gene expression in the mouse uterus </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Reproductive Biology and Endocrinology 7(1): 77-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7827(2009)7:1&#x0003c;77&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7827</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>In the mouse uterus, pregnancy is accompanied by changes in tachykinin and tachykinin receptor gene expression and in the uterotonic effects of endogenous tachykinins. In this study we have investigated whether changes in tachykinin expression and responses are a result of changes in ovarian steroid levels.</p></sec><sec sec-type="methods"><title>Methods</title><p>We quantified the mRNAs of tachykinins and tachykinin receptors in uteri from ovariectomized mice and studied their regulation in response to estrogen and progesterone using real-time quantitative RT-PCR. Early (3 h) and late (24 h) responses to estrogen were evaluated and the participation of the estrogen receptors (ER), ERalpha and ERbeta, was analyzed by treating mice with propylpyrazole triol, a selective ERalpha agonist, or diarylpropionitrile, a selective agonist of ERbeta.</p></sec><sec><title>Results</title><p>All genes encoding tachykinins (Tac1, Tac2 and Tac4) and tachykinin receptors (Tacr1, Tacr2 and Tacr3) were expressed in uteri from ovariectomized mice. Estrogen increased Tac1 and Tacr1 mRNA after 3 h and decreased Tac1 and Tac4 expression after 24 h. Tac2 and Tacr3 mRNA levels were decreased by estrogen at both 3 and 24 h. Most effects of estrogen were also observed in animals treated with propylpyrazole triol. Progesterone treatment increased the levels of Tac2.</p></sec><sec><title>Conclusion</title><p>These results show that the expression of tachykinins and their receptors in the mouse uterus is tightly and differentially regulated by ovarian steroids. Estrogen effects are mainly mediated by ERalpha supporting an essential role for this estrogen receptor in the regulation of the tachykinergic system in the mouse uterus.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Uterine function is tightly controlled by ovarian steroids [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. The physiological responses to acute estrogen (E<sub>2</sub>) occur in two temporally distinct steps. Early responses appear within the first 2&#x02013;3 h after E<sub>2 </sub>administration while late responses are observed 16&#x02013;24 h after E<sub>2</sub>, with each step involving activation of distinct sets of genes [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. E<sub>2 </sub>and progesterone (P<sub>4</sub>) exert their effects by binding to specific transcription factor receptors, the estrogen receptors &#x003b1; (ER&#x003b1;) and &#x003b2; (ER&#x003b2;) and the progesterone receptors (PR A and B), respectively [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. In addition to these classical genotropic effects, E<sub>2 </sub>and P<sub>4 </sub>activate extranuclear, non-genomic signaling cascades [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. It is still unclear whether non-genomic effects are mediated by membrane receptors distinct from the nuclear receptors, or additionally involve activation of classical ERs or PRs located outside the nucleus [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Accumulating evidence suggests that tachykinins (TKs) play a role in the regulation of uterine function [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. TKs comprise a family of peptides, which in mammals includes substance P (SP), neurokinin A (NKA) neurokinin B (NKB) and hemokinin-1 (HK) [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. In mice, SP and NKA are encoded by the <italic>Tac1 </italic>gene (accession number NM_009311), NKB by the <italic>Tac2 </italic>gene (accession number ENSMUST00000026466) and HK by the <italic>Tac4 </italic>gene (accession number NM_053093) [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Their biological effects are mediated by receptors belonging to the family of G protein-coupled receptors. Three different tachykinin receptors are currently recognized, namely the NK<sub>1 </sub>receptor (NK<sub>1</sub>R), the NK<sub>2 </sub>receptor (NK<sub>2</sub>R) and the NK<sub>3 </sub>receptor (NK<sub>3</sub>R) which, in mice, are encoded by the <italic>Tacr1</italic>(accession number NM_009313), <italic>Tacr2 </italic>(accession number NM_009314) and <italic>Tacr3 </italic>(accession number NM_021382) genes, respectively [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. The endogenous tachykinins bind with differing affinities to each of the tachykinin receptors. Thus, the NK<sub>1</sub>R is activated preferentially by SP and HK, the NK<sub>2</sub>R by NKA and the NK<sub>3</sub>R by NKB [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Tachykinins modulate reproductive function at both central and peripheral levels [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B35">35</xref>]. In the central nervous system, SP, NKA and NKB are expressed in subpopulations of hypothalamic and pituitary neurons where they influence, and are influenced by, gonadotropin and gonadal steroid levels [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B22">22</xref>] and modulate the synthesis and/or secretion of oxytocin [<xref ref-type="bibr" rid="B28">28</xref>]. In the reproductive tract, these peptides are expressed in sensory nerves and in non-neuronal cells within the placenta, the ovary, the uterus [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B34">34</xref>], the testes and the prostate [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. They are also present in other reproductive cells including corpora lutea, oocytes and spermatozoa [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B37">37</xref>].</p><p>We have previously found that all genes encoding TKs and their receptors are expressed in the mammalian uteri and that their expression and function vary during the ovarian cycle, throughout pregnancy and with age, [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. In late pregnant and non-pregnant women, in rats, and in late pregnant mice, TKs induce myometrial contractions that are mediated mainly by the NK<sub>2</sub>R with minor participation of NK<sub>1 </sub>and NK<sub>3 </sub>receptors [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. In contrast, in non-pregnant mice, the predominant receptor mediating myometrial contractions is the NK<sub>1</sub>R, with NK<sub>2</sub>R playing a minor role [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. The reasons for this difference between species remain unclear. Indeed, little is known about the physiological mechanisms that regulate the expression of TKs and their receptors in mouse uterus and in particular the influence of ovarian steroids upon their expression.</p><p>In this study, we have analyzed the direct effects of the ovarian steroids E<sub>2 </sub>and P<sub>4 </sub>on the expression of <italic>Tac1, Tac2, Tac4, Tacr1, Tacr2 </italic>and <italic>Tacr3 </italic>in uteri from ovariectomized mice. In addition, we have investigated the effects of the selective agonist of the estrogen receptor &#x003b1; (ER&#x003b1;) propylpyrazole triol (PPT) [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B40">40</xref>], and the selective agonist of the estrogen receptor &#x003b2; (ER&#x003b2;) diarylpropionitrile (DPN) [<xref ref-type="bibr" rid="B7">7</xref>], in order to define the roles played by ER&#x003b1; and ER&#x003b2; in the regulation of TK and TK receptor gene expression. We have also analyzed the effects of estren, a selective activator of non-genomic E<sub>2 </sub>signaling pathways [<xref ref-type="bibr" rid="B8">8</xref>]. Because E<sub>2</sub>-induced changes in gene expression occur as early or late responses [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>], animals were treated with E<sub>2</sub>, PPT, DPN or estren for either 3 or 24 h.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Animals and treatments</title><p>Ethical approval for this study was obtained from Consejo Superior de Investigaciones Cient&#x000ed;ficas (Spain). Virgin female Swiss mice (7&#x02013;9 weeks, 20&#x02013;25 g) were purchased from Charles River Laboratories (Barcelona, Spain), housed at 22&#x000b0;C under controlled lighting (12:12-h light/dark cycle) and provided with food and water <italic>ad libitum</italic>. Animals were bilaterally ovariectomized under avertin anesthesia (250 mg/Kg, i.p.). Fifteen days later, they were left untreated (control, untreated mice) or treated s.c. with a) E<sub>2 </sub>(17&#x003b2;-estradiol benzoate, Sigma, 1 &#x003bc;g/mouse); b) the selective ER&#x003b1; agonist propylpyrazole triol (PPT, Tocris, Ellisville, MO, 75 &#x003bc;g/mouse); c) the selective ER&#x003b2; agonist diarylpropionitrile (DPN, Tocris, 100 &#x003bc;g/mouse); d) estren (Steraloids Newport, RI, 300 &#x003bc;g/mouse) or e) the same volume of vehicle (olive oil, 100 &#x003bc;l) (control, vehicle-treated mice). In all cases, uteri were collected 3 and 24 h after the injection. In a second set of experiments, mice were treated with a) P<sub>4 </sub>(Sigma, 2 mg/mouse per day for 2 days) or its vehicle, and uteri collected 24 h after the last injection; b) a single injection of E<sub>2 </sub>(1 &#x003bc;g/mouse) or its vehicle, followed 24 h later by P<sub>4 </sub>(2 mg/mouse per day for 2 days) or its vehicle and uteri collected 24 h after the last injection; c) a single injection of E<sub>2 </sub>(1 &#x003bc;g/mouse) or its vehicle and uteri collected 72 h after treatment. The pharmacological doses of steroid receptor ligands used in the present experiments were based on previously published studies [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B39">39</xref>].</p></sec><sec><title>Real-time RT-PCR</title><p>Uterine samples were rapidly immersed in RNAlater (Ambion, Huntingdon, UK) and stored at -80&#x000b0;C until use. Total RNA isolation and cDNA synthesis were carried out as previously described [<xref ref-type="bibr" rid="B29">29</xref>]. The cDNA samples were amplified by PCR using specific oligonucleotide primer pairs (Table <xref ref-type="table" rid="T1">1</xref>) designed with the software Primer 3 and purchased from Sigma-Genosys (Cambridge, UK) [<xref ref-type="bibr" rid="B29">29</xref>]. A specific probe (n&#x000b0; 88, Home probe Library, Exiqon, Vedbaek, Denmark), chosen with the program Probefinder assay design (Exiqon), was used to detect the <italic>Tac1 </italic>transcript (88 bp) since this gene was present in faint amounts in uteri from pregnant and non-pregnant mice [<xref ref-type="bibr" rid="B29">29</xref>]. With this approach, we found that <italic>Tac1 </italic>mRNA levels were 4.5- and 3.0-fold higher in untreated ovariectomized mice, than in estrus and diestrus virgin mice, respectively (unpublished observations). The specific primer pair shown in Table <xref ref-type="table" rid="T1">1</xref> was employed in subsequent experiments for <italic>Tac1 </italic>detection. Table <xref ref-type="table" rid="T1">1</xref> also shows the primers used to amplify &#x003b2;-actin (<italic>Actb</italic>), protein phosphatase 1 catalytic subunit beta-isoform (<italic>Ppp1cb</italic>), glyceraldehyde-3-phosphate-dehydrogenase (<italic>Gapdh</italic>) and polymerase (RNA) II (DNA directed) polypeptide A (<italic>Polr2a</italic>), which were chosen as housekeeping genes for normalizing the PCR data on the basis of previous studies in the mouse and rat uterus [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Nucleotide sequence of the specific primers used in PCR amplifications.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Gene</td><td align="left">Primers</td><td align="left">Sense</td><td align="center">Product Size</td></tr></thead><tbody><tr><td align="left"><italic>Tac1</italic></td><td align="left">5'-GGCCAAGGAGAGCAAAGA-3'</td><td align="left">F</td><td align="center">88 bp</td></tr><tr><td></td><td align="left">5'-CGAGGATTTTCATGTTCGATT-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Tac2</italic></td><td align="left">5'-TCTGGAAGGATTGCTGAAAGTG-3'</td><td align="left">F</td><td align="center">302 bp</td></tr><tr><td></td><td align="left">5'-GTAGGGAAGGGAGCCAACAG-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Tac4</italic></td><td align="left">5'-GTAGCTTCCTCAGCCATGCAG-3</td><td align="left">F</td><td align="center">186 bp</td></tr><tr><td></td><td align="left">5'-CCGCCCCCAAATACAATACA-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Tacr1</italic></td><td align="left">5'-GCCAGAACATCCCAACAGG-3'</td><td align="left">F</td><td align="center">223 bp</td></tr><tr><td></td><td align="left">5'-GGCGAAGGTACACACAACCA-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Tacr2</italic></td><td align="left">5'-TGGTACTGGTGGTGGTGACATT-3'</td><td align="left">F</td><td align="center">251 bp</td></tr><tr><td></td><td align="left">5'-CCTGTCTTCCTCGGTTGGTG-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Tacr3</italic></td><td align="left">5'-CCAACTACTGCCGCTTCCA-3'</td><td align="left">F</td><td align="center">272 bp</td></tr><tr><td></td><td align="left">5'-GAAATGTTGCTTGGGACCTTCT-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Actb</italic></td><td align="left">5'-TCCCTGGAGAAGAGCTACGA-3'</td><td align="left">F</td><td align="center">362 bp</td></tr><tr><td></td><td align="left">5'-ATCTGCTGGAAGGTGGACAG-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Gapdh</italic></td><td align="left">5'-CAATGCCTCCTGCACCAC-3'</td><td align="left">F</td><td align="center">350 bp</td></tr><tr><td></td><td align="left">5'-CCTGCTTCACCACCTTCTTG-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Ppp1cb</italic></td><td align="left">5'-AACCATGAGTGTGCTAGCATCA-3'</td><td align="left">F</td><td align="center">472 bp</td></tr><tr><td></td><td align="left">5'-CACCAGCATTGTCAAACTCGCC-3'</td><td align="left">R</td><td></td></tr><tr><td align="left"><italic>Polr2a</italic></td><td align="left">5'-CGTTTCCATCCTAAGCCCAGT-3'</td><td align="left">F</td><td align="center">260 bp</td></tr><tr><td></td><td align="left">5'-ATCTCTGCCCGTGTTTCCAG-3'</td><td align="left">R</td><td></td></tr></tbody></table><table-wrap-foot><p>Shown are the structures of forward (F) and reverse (R) primers of indicated target genes and the size expected for each PCR-amplified product. Primers for <italic>Actb </italic>(&#x003b2;-actin), <italic>Gapdh</italic>, <italic>Ppp1cb and Polr2a</italic>, used as housekeeping genes, are also shown.</p></table-wrap-foot></table-wrap><p>Real-time quantitative PCR was performed on a Bio-Rad iCycler iQ real-time detection apparatus (Bio-Rad Laboratories, Hercules, CA) using a FastStart SYBR Green Master (Roche Diagnostics GmbH, Manheim, Germany). The parameters of PCR amplification were: 10 sec at 94&#x000b0;C, 20 sec at 60&#x000b0;C and 30 seconds at 72&#x000b0;C, for 45 cycles. The identity of each product was established by DNA sequence analysis [<xref ref-type="bibr" rid="B29">29</xref>] and the specificity of PCR reactions was confirmed by melting curve analysis of the products and by size verification of the amplicon in a conventional agarose gel.</p><p>Real-time PCR data were expressed as the fold change of the target gene expression relative to the geometric mean (g.m.) mRNA expression of the housekeeping genes in each sample, as described by Vandesompele et al. [<xref ref-type="bibr" rid="B41">41</xref>]. The fold change in gene expression was calculated by the formula: <inline-formula><inline-graphic xlink:href="1477-7827-7-77-i1.gif"/></inline-formula>, where C<sub>T </sub>is the threshold cycle, calculated by the iCycler software, &#x00394;C<sub>T </sub>= (C<sub>T</sub>target gene &#x02013; C<sub>T</sub>g.m.reference genes) and &#x00394;&#x00394;C<sub>T </sub>= (&#x00394;C<sub>T </sub>test sample - &#x00394;C<sub>T </sub>control sample). A pool of uterine cDNAs from untreated, ovariectomized mice, was used as a control sample throughout the study and the ratio of the target gene mRNA/geometric mean of the four reference genes mRNA in this control sample was designated as 1. Each assay was performed in triplicate and negative controls were run for every assay.</p></sec><sec><title>Data analysis</title><p>All values are expressed as the mean &#x000b1; S.E.M; <italic>n </italic>represents the number of mice used. Statistical procedures included one-way ANOVA followed by Dunnett's test for multiple comparisons and Student's unpaired <italic>t </italic>test to compare the means of two groups using <underline>GRAPHPAD PRISM</underline> 4. Statistical significance was accepted when <italic>P </italic>&#x0003c; 0.05.</p></sec></sec><sec><title>Results</title><p>The transcripts for <italic>Tac1</italic>, <italic>Tac2</italic>, <italic>Tac4</italic>, <italic>Tacr1</italic>, <italic>Tacr2 </italic>and <italic>Tacr3 </italic>were detected in uteri from ovariectomized mice. In all experiments and with all target genes, mRNA expression values were similar in untreated and vehicle-treated mice (Fig. <xref ref-type="fig" rid="F1">1</xref>, Fig. <xref ref-type="fig" rid="F2">2</xref>, Fig. <xref ref-type="fig" rid="F3">3</xref> and Fig. <xref ref-type="fig" rid="F4">4</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Real-time quantitative PCR analysis of A) <italic>Tac1</italic>; B) <italic>Tac2 </italic>and C) <italic>Tac4 </italic>expression in uterine cDNA from mice treated with E<sub>2</sub>, propylpyrazole triol (PPT), diarylpropionitrile (DPN)or estren</bold>. Uteri were collected from ovariectomized mice untreated (control) or treated for 3 or 24 h with E<sub>2 </sub>(1 &#x003bc;g/mouse) PPT (75 &#x003bc;g/mouse) DPN (100 &#x003bc;g/mouse) estren (300 &#x003bc;g/mouse) or the corresponding vehicle. Values are expressed as the fold change of each target-gene expression, relative to the geometric mean mRNA expression of 4 housekeeping genes. Each bar represents the mean of uterine cDNA samples from 5&#x02013;10 different mice, with S.E.M. shown by vertical lines. *<italic>P </italic>&#x0003c; 0.05, significant difference versus mRNA levels in uteri from ovariectomized mice treated for 3 h with vehicle; <sup>&#x02666;</sup><italic>P </italic>&#x0003c; 0.05, significant difference versus mRNA levels in uteri from ovariectomized mice treated for 24 h with vehicle; one-way ANOVA.</p></caption><graphic xlink:href="1477-7827-7-77-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Real-time quantitative PCR analysis of A) <italic>Tac1</italic>; B) <italic>Tac2 </italic>and C) <italic>Tac4 </italic>expression in uterine cDNA from mice treated with E<sub>2 </sub>and P<sub>4</sub>, alone or in combination</bold>. Uteri were collected from ovariectomized mice untreated (control) or treated with E<sub>2 </sub>(1 &#x003bc;g/mouse, 72 h) or its vehicle, P<sub>4 </sub>(2 mg/mouse per day for 2 days) or its vehicle, and E<sub>2 </sub>+ P<sub>4 </sub>or the corresponding vehicles. Values are expressed as the fold change of each target-gene expression, relative to the geometric mean mRNA expression of 4 housekeeping genes. Each bar represents the mean of uterine cDNA samples from 5&#x02013;10 different mice, with S.E.M. shown by vertical lines. <sup>a</sup><italic>P </italic>&#x0003c; 0.05, E<sub>2 </sub>vs. E<sub>2 </sub>vehicle, unpaired <italic>t </italic>test; <sup>b</sup><italic>P </italic>&#x0003c; 0.05, P<sub>4 </sub>vs. P<sub>4 </sub>vehicle, unpaired <italic>t </italic>test; <sup>c</sup><italic>P </italic>&#x0003c; 0.05, E<sub>2 </sub>+ P<sub>4</sub>, E<sub>2 </sub>+ P<sub>4 </sub>vehicle and E<sub>2 </sub>vehicle + P<sub>4 </sub>vs. E<sub>2 </sub>vehicle + P<sub>4 </sub>vehicle, one-way ANOVA.</p></caption><graphic xlink:href="1477-7827-7-77-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Real-time quantitative PCR analysis of A) <italic>Tacr1</italic>; B) <italic>Tacr2 </italic>and C) <italic>Tacr3 </italic>in uterine cDNA from mice treated with E<sub>2</sub>, propylpyrazole triol (PPT), diarylpropionitrile (DPN)or estren</bold>. Uteri were collected from ovariectomized mice untreated (control) or treated for 3 or 24 h with E<sub>2 </sub>(1 &#x003bc;g/mouse) PPT (75 &#x003bc;g/mouse) DPN (100 &#x003bc;g/mouse) estren (300 &#x003bc;g/mouse) or the corresponding vehicle. Values are expressed as the fold change of each target-gene expression relative to the geometric mean mRNA expression of 4 housekeeping genes. Each bar represents the mean of uterine cDNA samples from at least five different mice, with SEM shown by vertical lines. *<italic>P </italic>&#x0003c; 0.05, significant difference versus mRNA levels in uteri from ovariectomized mice treated for 3 h with vehicle; <sup>&#x02666;</sup><italic>P </italic>&#x0003c; 0.05, significant difference versus mRNA levels in uteri from ovariectomized mice treated for 24 h with vehicle; one-way ANOVA.</p></caption><graphic xlink:href="1477-7827-7-77-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Real-time quantitative PCR analysis of A) <italic>Tacr1</italic>; B) <italic>Tacr2 </italic>and C) <italic>Tacr3 </italic>expression in uterine cDNA from mice treated with E<sub>2 </sub>and P<sub>4</sub>, alone or in combination</bold>. Uteri were collected from ovariectomized mice untreated (control) or treated with E<sub>2 </sub>(1 &#x003bc;g/mouse, 72 h) or its vehicle, P<sub>4 </sub>(2 mg/mouse per day for 2 days) or its vehicle, and E<sub>2 </sub>+ P<sub>4 </sub>or the corresponding vehicles. Values are expressed as the fold change of each target-gene expression, relative to the geometric mean mRNA expression of 4 housekeeping genes. Each bar represents the mean of uterine cDNA samples from 5&#x02013;10 different mice, with S.E.M. shown by vertical lines. <sup>a</sup><italic>P </italic>&#x0003c; 0.05, E<sub>2 </sub>vs. E<sub>2 </sub>vehicle, unpaired <italic>t </italic>test; <sup>c</sup><italic>P </italic>&#x0003c; 0.05, E<sub>2 </sub>+ P<sub>4</sub>, E<sub>2 </sub>+ P<sub>4 </sub>vehicle and E<sub>2 </sub>vehicle + P<sub>4 </sub>vs. E<sub>2 </sub>vehicle + P<sub>4 </sub>vehicle, one-way ANOVA.</p></caption><graphic xlink:href="1477-7827-7-77-4"/></fig><sec><title>Effects on tachykinin gene expression</title><p><italic>Tac1 </italic>expression was increased 3-fold in uterine cDNA from mice treated with E<sub>2 </sub>for 3 h, compared with vehicle-treated (3 h) mice (Fig. <xref ref-type="fig" rid="F1">1A</xref>). PPT, DPN and estren also increased the <italic>Tac1 </italic>transcript 3 h after their administration (Fig. <xref ref-type="fig" rid="F1">1A</xref>). At 24 h, E<sub>2 </sub>decreased 7-fold the expression of <italic>Tac1 </italic>compared to the respective vehicle controls (Fig. <xref ref-type="fig" rid="F1">1A</xref>). Treatment with PPT for 24 h caused a 5-fold decrease in <italic>Tac1 </italic>mRNA while DNP and estren had no significant effects (Fig <xref ref-type="fig" rid="F1">1A</xref>). <italic>Tac1 </italic>mRNA levels remained low in mice after 72 h treatment with E<sub>2 </sub>(Fig. <xref ref-type="fig" rid="F2">2A</xref>). P<sub>4 </sub>was without effect and did not influence the E<sub>2</sub>-induced decrease in <italic>Tac1 </italic>expression (Fig. <xref ref-type="fig" rid="F2">2A</xref>).</p><p>Treatment with E<sub>2 </sub>for 3 or 24 h caused large decreases in <italic>Tac2 </italic>expression, compared with vehicle-treated mice (Fig. <xref ref-type="fig" rid="F1">1B</xref>). The decrease was still significant at 72 h (P &#x0003c; 0.05, see Fig. <xref ref-type="fig" rid="F2">2B</xref>). PPT decreased <italic>Tac2 </italic>mRNA after 3 and 24 h treatment, while neither DPN nor estren had significant effects (P &#x0003e; 0.05, Fig. <xref ref-type="fig" rid="F2">2B</xref>). <italic>Tac2 </italic>mRNA was increased 3-fold in mice treated with P<sub>4 </sub>(Fig. <xref ref-type="fig" rid="F2">2B</xref>); neither this increase nor the E<sub>2</sub>-induced decrease were seen in mice treated with both E<sub>2 </sub>and P<sub>4 </sub>(Fig. <xref ref-type="fig" rid="F2">2B</xref>).</p><p><italic>Tac4 </italic>mRNA levels were decreased 3-fold in mice treated with E<sub>2 </sub>for 24 h, compared with uteri from corresponding vehicle-treated mice. As shown in Figs. <xref ref-type="fig" rid="F1">1C</xref> and <xref ref-type="fig" rid="F2">2C</xref>, none of the other treatments modified <italic>Tac4 </italic>expression.</p></sec><sec><title>Effects on tachykinin receptor gene expression</title><p><italic>Tacr1 </italic>expression was increased in mice treated for 3 h with E<sub>2 </sub>or PPT (Fig. <xref ref-type="fig" rid="F3">3A</xref>). After treatment with E<sub>2 </sub>or PPT for 24 h, the mRNA levels were similar to those observed in control, vehicle-treated mice. DPN and estren had no effects either at 3 or 24 h (Fig. <xref ref-type="fig" rid="F3">3A</xref>). P<sub>4</sub>, alone or in combination with E<sub>2</sub>, was without effect on <italic>Tacr1 </italic>levels (Fig. <xref ref-type="fig" rid="F4">4A</xref>).</p><p>Compared with uteri from control, vehicle-treated mice, E<sub>2 </sub>and P<sub>4 </sub>(alone or in combination), PPT, DPN and estren did not cause significant alterations in <italic>Tacr2 </italic>mRNA levels (P &#x0003e; 0.05, Figs. <xref ref-type="fig" rid="F3">3B</xref> and <xref ref-type="fig" rid="F4">4B</xref>).</p><p><italic>Tacr3 </italic>expression was decreased in mice treated with E<sub>2 </sub>for 3 or 24 h and in mice treated with PPT for 24 h, compared with vehicle-treated mice (Fig. <xref ref-type="fig" rid="F3">3C</xref>). DPN and estren had no effect (Fig. <xref ref-type="fig" rid="F3">3C</xref>). <italic>Tacr3 </italic>mRNA levels remained low in uteri from mice treated with E<sub>2 </sub>for 72 h (Fig. <xref ref-type="fig" rid="F4">4C</xref>). P<sub>4 </sub>did not modify <italic>Tacr3 </italic>expression and did not influence the E<sub>2</sub>-induced decrease in the expression of <italic>Tacr3 </italic>(Fig. <xref ref-type="fig" rid="F4">4C</xref>).</p></sec></sec><sec><title>Discussion</title><p>The present study has shown that ovarian steroids tightly and differentially regulate the expression of tachykinin and tachykinin receptor genes in the mouse uteri. Since the uterus is often considered a model to investigate the effects of steroid hormones on gene transcription, this study represents the first analysis of the regulatory effects of E<sub>2 </sub>and P<sub>4 </sub>on the whole tachykinin family.</p><p><italic>Tac1 </italic>mRNA and the tachykinin peptides encoded by this gene, predominantly SP and NKA, are widely expressed in neuronal and non-neuronal cells at both central and peripheral levels [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. Several workers have investigated the effects of ovarian steroids on the expression of this gene and its protein products in the CNS, particularly in the hypothalamic-pituitary axis [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B32">32</xref>], often with conflicting results. Our findings show that <italic>Tac1 </italic>was regulated by E<sub>2 </sub>in a complex and time-dependent manner, with both stimulatory and inhibitory effects. The higher expression of <italic>Tac1 </italic>in ovariectomized animals, compared to non-ovariectomized mice [<xref ref-type="bibr" rid="B29">29</xref>], together with the observation that 24&#x02013;72 h treatment with E<sub>2 </sub>causes a strong and long-lasting down-regulation of the <italic>Tac1 </italic>transcript clearly points to the importance of <italic>Tac1 </italic>regulation by estrogen. In contrast to E<sub>2</sub>, P<sub>4 </sub>had no effect on <italic>Tac1 </italic>expression nor did it influence the E<sub>2</sub>-induced decrease.</p><p>In the mouse uterus there is a predominance of ER&#x003b1;, while ER&#x003b2; modulates some of its effects [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. In our study, the E<sub>2 </sub>effect was mimicked by PPT, a highly selective agonist of ER&#x003b1; devoid of activity on ER&#x003b2; [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. In contrast DPN, a highly selective agonist of ER&#x003b2; [<xref ref-type="bibr" rid="B7">7</xref>], or estren, a purported activator of non-genomic E<sub>2 </sub>signaling [<xref ref-type="bibr" rid="B8">8</xref>], were without effect. It thus seems likely that nuclear ER&#x003b1; mediates the inhibitory effect of E<sub>2 </sub>(after 24 h) on <italic>Tac1 </italic>expression.</p><p>Early physiological responses of the mouse uterus to acute E<sub>2 </sub>appear within the first 2&#x02013;3 h while late responses are observed 16&#x02013;24 h after E<sub>2 </sub>[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Consistent with these findings, 3 h treatment with E<sub>2 </sub>caused an increase in <italic>Tac1 </italic>mRNA levels. This early response was also observed in animals treated with PPT, DPN or estren. These findings suggest that early stimulation of <italic>Tac1 </italic>is mediated by both genomic and non-genomic E<sub>2 </sub>pathways.</p><p>The NK<sub>1</sub>R is the preferred receptor for SP, while NKA can also act as a potent agonist on NK<sub>1</sub>R [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Therefore, it was interesting to observe that treatment with E<sub>2 </sub>for 3 h caused a parallel increase in both <italic>Tac1 </italic>and <italic>Tacr1 </italic>mRNAs. <italic>Tacr1 </italic>gene expression was also increased in mice treated for 3 h with PPT revealing the participation of ER&#x003b1;. Since tachykinins are potent inflammatory mediators, the present findings may suggest that SP(NKA)-NK<sub>1</sub>R ligand-receptor pair could play a role in mediating rapid effects of E<sub>2 </sub>in the uterus, such as hyperemia, water imbibition and attraction of immune cells.</p><p>Treatment of ovariectomized mice with E<sub>2</sub>, PPT, DPN or P<sub>4 </sub>did not decrease NK<sub>1</sub>R gene expression. This finding was unexpected, as we previously found that the transcript for <italic>Tacr1 </italic>decreases by about 11-fold on day 17 of pregnancy, compared with its expression in uteri from non-pregnant mice [<xref ref-type="bibr" rid="B29">29</xref>]. The NK<sub>1</sub>R is regulated by many different mechanisms and it may be that near term, in addition to ovarian steroids, other hormonal, humoral, placental or neural influences may influence its expression.</p><p>The NK<sub>2</sub>R is the key tachykinin receptor mediating contractile responses to TKs in the near term uteri from all mammalian species studied [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Furthermore, the participation of the NK<sub>2</sub>R in mouse myometrial contractions is higher under conditions of estrogen dominance [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B39">39</xref>]. The expression of <italic>Tacr2 </italic>in uteri from ovariectomized mice was, however, unaffected by treatment with E<sub>2 </sub>or P<sub>4</sub>. This result is consistent with our previous observation that <italic>Tacr2 </italic>mRNA levels are similar in uteri from pregnant or non-pregnant mice and remain essentially constant during different hormonal stages [<xref ref-type="bibr" rid="B29">29</xref>]. Taken together, these findings suggest that, at least in the mouse uterus, the <italic>Tacr2 </italic>gene is not a direct target for ovarian steroids. The increased response in late pregnancy to agonists that act at the NK<sub>2</sub>R [<xref ref-type="bibr" rid="B29">29</xref>] may therefore reflect regulation at a posttranscriptional level.</p><p>NKB, together with SP, kisspeptin and dinorphin, is present in a group of hypothalamic neurons that also express estrogen and progesterone receptors [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B42">42</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. NKB is also expressed at all main levels in the female genital tract [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B33">33</xref>] and its excessive secretion from the placenta may cause, in part, some of the symptoms of pre-eclampsia [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Recently, the genome sequence of a non-placental mammal, namely the platypus <italic>Ornithorhynchus anatinus</italic>, has become available [<xref ref-type="bibr" rid="B44">44</xref>] and by phylogenetic analysis, we found that the NKB encoding gene is present (Ensemble entry ENSOANG00000022075). This finding clearly shows that NKB plays additional roles in reproduction, apart from its participation in placental pathophysiology.</p><p>NKB is elevated in the human female hypothalamus after menopause [<xref ref-type="bibr" rid="B21">21</xref>]. Additionally, its expression in the rodent brain and in the rat uterus is increased by age and ovariectomy and decreased by E<sub>2 </sub>treatment [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. These findings and our current observations showing that <italic>Tac2 </italic>mRNA is strongly repressed in uteri from young ovariectomized mice treated with E<sub>2 </sub>at all times of treatment indicate that at both central and peripheral levels, NKB over-expression is secondary to ovarian failure [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B38">38</xref>].</p><p><italic>Tac2 </italic>inhibition was mediated by ER&#x003b1; because it was observed in mice treated for 3 or 24 h with PPT, but not with DPN or estren. In addition, our data show, to our knowledge for the first time, that P<sub>4 </sub>treatment up-regulated <italic>Tac2 </italic>gene expression in uteri from ovariectomized mice. The mechanism that mediates this P<sub>4 </sub>effect remains unclear, as in ovariectomized mice, the expression of PRs fall as a consequence of the lack of E<sub>2 </sub>[<xref ref-type="bibr" rid="B7">7</xref>]. Although the presence of a basal population of nuclear PRs cannot be excluded, the effects on <italic>Tac2 </italic>expression may more probably be mediated by activation of membrane-bound P<sub>4 </sub>receptors distinct from PRs. Several P<sub>4 </sub>membrane receptor candidates are present in uteri from ovariectomized mice and the expression of some of them is increased by P<sub>4 </sub>[<xref ref-type="bibr" rid="B9">9</xref>]. Up-regulation by P<sub>4 </sub>would permit a local increase in <italic>Tac2 </italic>expression following ovulation or in the case of copulation and successful fertilization. These data are in agreement with our previous observations showing that the highest <italic>Tac2 </italic>levels were found in the mouse uterus around the time of implantation and that these were strongly decreased at late pregnancy [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>At the peripheral level the role of NK<sub>3</sub>R, like that of its preferred ligand NKB, remains poorly understood [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B45">45</xref>]. The present data show that E<sub>2 </sub>strongly reduces <italic>Tacr3 </italic>expression in uteri from ovariectomized mice. The E<sub>2</sub>-induced responses were mimicked by PPT but not by DPN or estren, providing the first evidence, to our knowledge, that the effects of E<sub>2 </sub>on this receptor are mediated by ER&#x003b1;. The observation that E<sub>2 </sub>caused a rapid and concomitant down-regulation of <italic>Tac2 </italic>and <italic>Tacr3 </italic>expression supports the existence of an important link between E<sub>2 </sub>and the NK<sub>3</sub>R/NKB activation pathway [<xref ref-type="bibr" rid="B38">38</xref>]. Moreover, the tight regulation of both genes strongly argues for a role of NKB, acting through the NK<sub>3</sub>R, in mediating some of the effects of E<sub>2 </sub>and P<sub>4 </sub>on uterine function [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. In this context, a recent report has established a correlation between familial hypogonadotropic hypogonadism and mutations in the human genes <italic>TAC3 </italic>and <italic>TACR3</italic>&#x000b7;[<xref ref-type="bibr" rid="B23">23</xref>] providing clear evidence for the importance of NKB and the NK<sub>3</sub>R in reproduction.</p><p>The <italic>Tac4 </italic>gene is expressed in the placenta, the ovary, the uterus, and also in oocytes and blastocyst-stage embryos [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B37">37</xref>]. In the mouse uteri, HK caused myometrial contractions that are mediated by the NK<sub>1</sub>R and are decreased at late pregnancy [<xref ref-type="bibr" rid="B39">39</xref>]. Apart from its effects on myometrial contractility, the physiological role of HK at the reproductive level remains poorly understood and its direct regulation by ovarian steroids has not been studied. The present data show that the <italic>Tac4 </italic>gene is also a target of E<sub>2 </sub>and suggest that <italic>Tac4 </italic>expression is down-regulated by E<sub>2 </sub>surges, as those observed in mammals before ovulation or near labor.</p></sec><sec><title>Conclusion</title><p>This study suggests that uterine tachykinins and tachykinin receptors are important targets of ovarian steroids and particularly of E<sub>2</sub>, acting at ER&#x003b1;. The whole tachykinergic system appears involved in the regulation of reproductive functions.</p></sec><sec><title>Abbreviations</title><p>SP: substance P; NKA: neurokinin A; NKB: neurokinin B; HK1: hemokinin 1; TK: tachykinin; NK<sub>1</sub>R: NK<sub>1 </sub>receptor; NK<sub>2</sub>R: NK<sub>2 </sub>receptor; NK<sub>3</sub>R: NK<sub>3 </sub>receptor; E<sub>2</sub>: estrogen; ER&#x003b1;: estrogen receptor &#x003b1;; ER&#x003b2;: estrogen receptor &#x003b2;; PPT: propylpyrazole triol; DPN: diarylpropionitrile; P<sub>4</sub>: progesterone; PR: progesterone receptor; CNS: central nervous system.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>FMP carried out PCR experiments and helped to write the manuscript. COP performed ovariectomy, ovarian steroid treatments and collected uterine samples. EP performed the statistical analysis. JNP and LC wrote the manuscript. FMP and LC designed the study. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from Ministerio de Educaci&#x000f3;n y Ciencia (BFU2005-04495-C02-01/BFI and CTQ2007-61024/BQU) and Junta de Andaluc&#x000ed;a (FQM261), Spain.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wray</surname><given-names>S</given-names></name><name><surname>Noble</surname><given-names>K</given-names></name></person-group><article-title>Sex hormones and excitation-contraction coupling in the uterus: the effects of oestrous and hormones</article-title><source>J Neuroendocrinol</source><year>2008</year><volume>20</volume><fpage>451</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">18266942</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2826.2008.01665.x</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>WG</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Das</surname><given-names>SK</given-names></name><name><surname>Paria</surname><given-names>BC</given-names></name><name><surname>Dey</surname><given-names>SK</given-names></name></person-group><article-title>Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>2963</fpage><lpage>2968</lpage><pub-id pub-id-type="pmid">12601161</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0530162100</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Candenas</surname><given-names>L</given-names></name><name><surname>Lecci</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Patak</surname><given-names>E</given-names></name><name><surname>Maggi</surname><given-names>CA</given-names></name><name><surname>Pennefather</surname><given-names>JN</given-names></name></person-group><article-title>Tachykinins and tachykinin receptors: effects in the genitourinary tract</article-title><source>Life Sci</source><year>2005</year><volume>76</volume><fpage>835</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">15589963</pub-id><pub-id pub-id-type="doi">10.1016/j.lfs.2004.10.004</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>SC</given-names></name><name><surname>Deroo</surname><given-names>BJ</given-names></name><name><surname>Hansen</surname><given-names>K</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Grissom</surname><given-names>S</given-names></name><name><surname>Afshari</surname><given-names>CA</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name></person-group><article-title>Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen</article-title><source>Mol Endocrinol</source><year>2003</year><volume>17</volume><fpage>2070</fpage><lpage>2083</lpage><pub-id pub-id-type="pmid">12893882</pub-id><pub-id pub-id-type="doi">10.1210/me.2003-0146</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>SC</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><name><surname>Grissom</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>K</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name></person-group><article-title>Estren behaves as a weak estrogen rather than a nongenomic selective activator in the mouse uterus</article-title><source>Endocrinology</source><year>2006</year><volume>147</volume><fpage>2203</fpage><lpage>2214</lpage><pub-id pub-id-type="pmid">16469803</pub-id><pub-id pub-id-type="doi">10.1210/en.2005-1292</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weihua</surname><given-names>Z</given-names></name><name><surname>Saji</surname><given-names>S</given-names></name><name><surname>M&#x000e4;kinen</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Jensen</surname><given-names>EV</given-names></name><name><surname>Warner</surname><given-names>M</given-names></name><name><surname>Gustafsson</surname><given-names>JA</given-names></name></person-group><article-title>Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>5936</fpage><lpage>5941</lpage><pub-id pub-id-type="pmid">10823946</pub-id><pub-id pub-id-type="doi">10.1073/pnas.97.11.5936</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrido-Gracia</surname><given-names>JC</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Bellido</surname><given-names>C</given-names></name><name><surname>Aguilar</surname><given-names>R</given-names></name><name><surname>Barranco</surname><given-names>I</given-names></name><name><surname>Millan</surname><given-names>Y</given-names></name><name><surname>de las Mulas</surname><given-names>JM</given-names></name><name><surname>Sanchez-Criado</surname><given-names>JE</given-names></name></person-group><article-title>The integrated action of estrogen receptor isoforms and sites with progesterone receptor in the gonadotrope modulates LH secretion: evidence from tamoxifen-treated ovariectomized rats</article-title><source>J Endocrinol</source><year>2007</year><volume>193</volume><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">17400808</pub-id><pub-id pub-id-type="doi">10.1677/JOE-06-0214</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>O'brien</surname><given-names>CA</given-names></name><name><surname>Kousteni</surname><given-names>S</given-names></name><name><surname>Manolagas</surname><given-names>SC</given-names></name></person-group><article-title>Classical genotropic versus kinase-initiated regulation of gene transcription by the estrogen receptor alpha</article-title><source>Endocrinology</source><year>2006</year><volume>147</volume><fpage>1986</fpage><lpage>1996</lpage><pub-id pub-id-type="pmid">16384865</pub-id><pub-id pub-id-type="doi">10.1210/en.2005-1314</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kanda</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>DJ</given-names></name><name><surname>Ecker</surname><given-names>JL</given-names></name><name><surname>Losel</surname><given-names>R</given-names></name><name><surname>Wehling</surname><given-names>M</given-names></name><name><surname>Peluso</surname><given-names>JJ</given-names></name><name><surname>Pru</surname><given-names>JK</given-names></name></person-group><article-title>Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and human</article-title><source>Mol Cell Endocrinol</source><year>2008</year><volume>287</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18440126</pub-id><pub-id pub-id-type="doi">10.1016/j.mce.2008.02.012</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pennefather</surname><given-names>JN</given-names></name><name><surname>Patak</surname><given-names>E</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>Mammalian tachykinins and uterine smooth muscle: the challenge escalates</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>500</volume><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">15464017</pub-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2004.07.007</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Satake</surname><given-names>H</given-names></name><name><surname>Kawada</surname><given-names>T</given-names></name></person-group><article-title>Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors</article-title><source>Curr Drug Targets</source><year>2006</year><volume>7</volume><fpage>963</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">16918325</pub-id><pub-id pub-id-type="doi">10.2174/138945006778019273</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>NM</given-names></name></person-group><article-title>Hemokinins and endokinins</article-title><source>Cell Mol Life Sci</source><year>2004</year><volume>61</volume><fpage>1652</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">15224188</pub-id><pub-id pub-id-type="doi">10.1007/s00018-004-4035-x</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Milne</surname><given-names>CD</given-names></name><name><surname>Paige</surname><given-names>CJ</given-names></name></person-group><article-title>Tachykinins in the immune system</article-title><source>Curr Drug Targets</source><year>2006</year><volume>7</volume><fpage>1011</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">16918329</pub-id><pub-id pub-id-type="doi">10.2174/138945006778019363</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>TA</given-names></name><name><surname>Rojo</surname><given-names>J</given-names></name><name><surname>Nieto</surname><given-names>PM</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>Tachykinins and tachykinin receptors: structure and activity relationships</article-title><source>Curr Med Chem</source><year>2004</year><volume>11</volume><fpage>2045</fpage><lpage>2081</lpage><pub-id pub-id-type="pmid">15279567</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerard</surname><given-names>NP</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Xiao-Ping</surname><given-names>H</given-names></name><name><surname>Gerard</surname><given-names>C</given-names></name></person-group><article-title>Molecular aspects of the tachykinin receptors</article-title><source>Regul Pept</source><year>1993</year><volume>43</volume><fpage>21</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">8381237</pub-id><pub-id pub-id-type="doi">10.1016/0167-0115(93)90404-V</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burcher</surname><given-names>E</given-names></name><name><surname>Mussap</surname><given-names>CJ</given-names></name><name><surname>Geraghty</surname><given-names>DP</given-names></name><name><surname>McClure-Sharp</surname><given-names>JM</given-names></name><name><surname>Watkins</surname><given-names>DJ</given-names></name></person-group><article-title>Concepts in characterization of tachykinin receptors</article-title><source>Ann N Y Acad Sci</source><year>1991</year><volume>632</volume><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">1719861</pub-id><pub-id pub-id-type="doi">10.1111/j.1749-6632.1991.tb33101.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecci</surname><given-names>A</given-names></name><name><surname>Giuliani</surname><given-names>S</given-names></name><name><surname>Tramontana</surname><given-names>M</given-names></name><name><surname>Carini</surname><given-names>F</given-names></name><name><surname>Maggi</surname><given-names>CA</given-names></name></person-group><article-title>Peripheral actions of tachykinins</article-title><source>Neuropeptides</source><year>2000</year><volume>34</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">11049734</pub-id><pub-id pub-id-type="doi">10.1054/npep.2000.0825</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Debeljuk</surname><given-names>L</given-names></name><name><surname>Lasaga</surname><given-names>M</given-names></name></person-group><article-title>Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide gamma</article-title><source>Peptides</source><year>1999</year><volume>20</volume><fpage>285</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">10422885</pub-id><pub-id pub-id-type="doi">10.1016/S0196-9781(98)00159-4</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rance</surname><given-names>NE</given-names></name></person-group><article-title>Menopause and the human hypothalamus: Evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback</article-title><source>Peptides</source><year>2009</year><volume>30</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">18614256</pub-id><pub-id pub-id-type="doi">10.1016/j.peptides.2008.05.016</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>ER</given-names></name><name><surname>Harlan</surname><given-names>RE</given-names></name><name><surname>Krause</surname><given-names>JE</given-names></name></person-group><article-title>Gonadal steroid regulation of substance P (SP) and SP-encoding messenger ribonucleic acids in the rat anterior pituitary and hypothalamus</article-title><source>Endocrinology</source><year>1990</year><volume>126</volume><fpage>330</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">1688409</pub-id><pub-id pub-id-type="doi">10.1210/endo-126-1-330</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rance</surname><given-names>NE</given-names></name><name><surname>Young</surname><given-names>WS</given-names><suffix>III</suffix></name></person-group><article-title>Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women</article-title><source>Endocrinology</source><year>1991</year><volume>128</volume><fpage>2239</fpage><lpage>2247</lpage><pub-id pub-id-type="pmid">1708331</pub-id><pub-id pub-id-type="doi">10.1210/endo-128-5-2239</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>P</given-names></name><name><surname>Lenoir</surname><given-names>V</given-names></name><name><surname>Kerdelhue</surname><given-names>B</given-names></name></person-group><article-title>Ovarian steroid modulation of neurokinin contents in hypothalamus, pituitary, trigeminal nucleus, and cervical spinal cord of the ovariectomized female rat</article-title><source>J Neuroendocrinol</source><year>1998</year><volume>10</volume><fpage>823</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">9831258</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2826.1998.00267.x</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Topaloglu</surname><given-names>AK</given-names></name><name><surname>Reimann</surname><given-names>F</given-names></name><name><surname>Guclu</surname><given-names>M</given-names></name><name><surname>Yalin</surname><given-names>AS</given-names></name><name><surname>Kotan</surname><given-names>LD</given-names></name><name><surname>Porter</surname><given-names>KM</given-names></name><name><surname>Serin</surname><given-names>A</given-names></name><name><surname>Mungan</surname><given-names>NO</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Ozbek</surname><given-names>MN</given-names></name><name><surname>Imamoglu</surname><given-names>S</given-names></name><name><surname>Akalin</surname><given-names>NS</given-names></name><name><surname>Yuksel</surname><given-names>B</given-names></name><name><surname>O'Rahilly</surname><given-names>S</given-names></name><name><surname>Semple</surname><given-names>RK</given-names></name></person-group><article-title>TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction</article-title><source>Nature Genet</source><year>2009</year><volume>41</volume><fpage>354</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">19079066</pub-id><pub-id pub-id-type="doi">10.1038/ng.306</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>NM</given-names></name><name><surname>Woods</surname><given-names>RJ</given-names></name><name><surname>Gardiner</surname><given-names>SM</given-names></name><name><surname>Lomthaisong</surname><given-names>K</given-names></name><name><surname>Gladwell</surname><given-names>RT</given-names></name><name><surname>Butlin</surname><given-names>DJ</given-names></name><name><surname>Manyonda</surname><given-names>IT</given-names></name><name><surname>Lowry</surname><given-names>PJ</given-names></name></person-group><article-title>Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia</article-title><source>Nature</source><year>2000</year><volume>405</volume><fpage>797</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">10866201</pub-id><pub-id pub-id-type="doi">10.1038/35015579</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>PJ</given-names></name></person-group><article-title>Has the mechanism by which the endocrine placenta scavenges the mother whilst sparing the foetus been unmasked?</article-title><source>J Mol Endocrinol</source><year>2003</year><volume>31</volume><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">14664698</pub-id><pub-id pub-id-type="doi">10.1677/jme.0.0310341</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Debeljuk</surname><given-names>L</given-names></name></person-group><article-title>Tachykinins and ovarian function in mammals</article-title><source>Peptides</source><year>2006</year><volume>27</volume><fpage>736</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">16165249</pub-id><pub-id pub-id-type="doi">10.1016/j.peptides.2005.08.002</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>P</given-names></name><name><surname>Lenoir</surname><given-names>V</given-names></name><name><surname>Kerdelhu&#x000e9;</surname><given-names>B</given-names></name></person-group><article-title>The in vitro effect of substance P on the GnRH-induced LH release depends on the steroidal environment and is reverted by a NK1 receptor antagonist (RP 67580) in the cycling female rat</article-title><source>Neuropeptides</source><year>1998</year><volume>32</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">9639246</pub-id><pub-id pub-id-type="doi">10.1016/S0143-4179(98)90023-3</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Juszczak</surname><given-names>M</given-names></name><name><surname>Boczek-Leszczyk</surname><given-names>E</given-names></name></person-group><article-title>Oxytocin release from the rat neurohypophysis into the blood: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists</article-title><source>J Physiol Pharmacol</source><year>2008</year><volume>59</volume><fpage>553</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">18953097</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patak</surname><given-names>E</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Story</surname><given-names>ME</given-names></name><name><surname>Pintado</surname><given-names>CO</given-names></name><name><surname>Fleming</surname><given-names>A</given-names></name><name><surname>Page</surname><given-names>NM</given-names></name><name><surname>Pennefather</surname><given-names>JN</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>Functional and molecular characterization of tachykinins and tachykinin receptors in the mouse uterus</article-title><source>Biol Reprod</source><year>2005</year><volume>72</volume><fpage>1125</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">15647454</pub-id><pub-id pub-id-type="doi">10.1095/biolreprod.104.036814</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patak</surname><given-names>E</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name><name><surname>Pennefather</surname><given-names>JN</given-names></name><name><surname>Ziccone</surname><given-names>S</given-names></name><name><surname>Lilley</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Mantecon</surname><given-names>AG</given-names></name><name><surname>Story</surname><given-names>ME</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name></person-group><article-title>Tachykinins and tachykinin receptors in human uterus</article-title><source>Br J Pharmacol</source><year>2003</year><volume>139</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">12788812</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjp.0705279</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>NM</given-names></name><name><surname>Dakour</surname><given-names>J</given-names></name><name><surname>Morrish</surname><given-names>DW</given-names></name></person-group><article-title>Gene regulation of neurokinin B and its receptor NK3 in late pregnancy and pre-eclampsia</article-title><source>Mol Hum Reprod</source><year>2006</year><volume>12</volume><fpage>427</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">16709596</pub-id><pub-id pub-id-type="doi">10.1093/molehr/gal025</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Saha</surname><given-names>SK</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>SS</given-names></name></person-group><article-title>Tachykinin family genes and their receptors are differentially expressed in the hypothyroid ovary and pituitary</article-title><source>Cell Physiol Biochem</source><year>2007</year><volume>20</volume><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">17762164</pub-id><pub-id pub-id-type="doi">10.1159/000107521</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brylla</surname><given-names>E</given-names></name><name><surname>Aust</surname><given-names>G</given-names></name><name><surname>Geyer</surname><given-names>M</given-names></name><name><surname>Uckermann</surname><given-names>O</given-names></name><name><surname>L&#x000f6;ffler</surname><given-names>S</given-names></name><name><surname>Spanel-Borowski</surname><given-names>K</given-names></name></person-group><article-title>Coexpression of preprotachykinin A and B transcripts in the bovine corpus luteum and evidence for functional neurokinin receptor activity in luteal endothelial cells and ovarian macrophages</article-title><source>Regul Pept</source><year>2005</year><volume>125</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">15582723</pub-id><pub-id pub-id-type="doi">10.1016/j.regpep.2004.08.003</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Armesto</surname><given-names>CP</given-names></name><name><surname>Magraner</surname><given-names>J</given-names></name><name><surname>Trujillo</surname><given-names>M</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>JD</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>Tachykinin receptor and neutral endopeptidase gene expression in the rat uterus: characterization and regulation in response to ovarian steroid treatment</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>2526</fpage><lpage>2532</lpage><pub-id pub-id-type="pmid">10342838</pub-id><pub-id pub-id-type="doi">10.1210/en.140.6.2526</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravina</surname><given-names>CG</given-names></name><name><surname>Seda</surname><given-names>M</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Orea</surname><given-names>A</given-names></name><name><surname>Fernandez-Sanchez</surname><given-names>M</given-names></name><name><surname>Pintado</surname><given-names>CO</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>A role for tachykinins in the regulation of human sperm motility</article-title><source>Hum Reprod</source><year>2007</year><volume>22</volume><fpage>1617</fpage><lpage>1625</lpage><pub-id pub-id-type="pmid">17437961</pub-id><pub-id pub-id-type="doi">10.1093/humrep/dem069</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Almeida</surname><given-names>TA</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Devillier</surname><given-names>P</given-names></name><name><surname>Advenier</surname><given-names>C</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>mRNA expression of tachykinins and tachykinin receptors in different human tissues</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>494</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">15212980</pub-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2004.05.016</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pintado</surname><given-names>CO</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Pennefather</surname><given-names>JN</given-names></name><name><surname>Hidalgo</surname><given-names>A</given-names></name><name><surname>Baamonde</surname><given-names>A</given-names></name><name><surname>Sanchez</surname><given-names>T</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>A role for tachykinins in female mouse and rat reproductive function</article-title><source>Biol Reprod</source><year>2003</year><volume>69</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">12773411</pub-id><pub-id pub-id-type="doi">10.1095/biolreprod.103.017111</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cintado</surname><given-names>CG</given-names></name><name><surname>Pinto</surname><given-names>FM</given-names></name><name><surname>Devillier</surname><given-names>P</given-names></name><name><surname>Merida</surname><given-names>A</given-names></name><name><surname>Candenas</surname><given-names>ML</given-names></name></person-group><article-title>Increase in neurokinin B expression and in tachykinin NK(3) receptor-mediated response and expression in the rat uterus with age</article-title><source>J Pharmacol Exp Ther</source><year>2001</year><volume>299</volume><fpage>934</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">11714879</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patak</surname><given-names>E</given-names></name><name><surname>Pennefather</surname><given-names>JN</given-names></name><name><surname>Gozali</surname><given-names>M</given-names></name><name><surname>Candenas</surname><given-names>L</given-names></name><name><surname>Kerr</surname><given-names>K</given-names></name><name><surname>Exintaris</surname><given-names>B</given-names></name><name><surname>Ziccone</surname><given-names>S</given-names></name><name><surname>Potteck</surname><given-names>H</given-names></name><name><surname>Chetty</surname><given-names>N</given-names></name><name><surname>Page</surname><given-names>NM</given-names></name><name><surname>Pinto</surname><given-names>F</given-names></name></person-group><article-title>Functional characterisation of hemokinin-1 in mouse uterus</article-title><source>Eur J Pharmacol</source><year>2008</year><volume>601</volume><fpage>148</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">18977217</pub-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.10.036</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Coletta</surname><given-names>CJ</given-names></name><name><surname>Tedesco</surname><given-names>R</given-names></name><name><surname>Nishiguchi</surname><given-names>G</given-names></name><name><surname>Carlson</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Katzenellenbogen</surname><given-names>BS</given-names></name><name><surname>Katzenellenbogen</surname><given-names>JA</given-names></name></person-group><article-title>Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-&#x003b1;-selective agonists</article-title><source>J Med Chem</source><year>2000</year><volume>43</volume><fpage>4934</fpage><lpage>4947</lpage><pub-id pub-id-type="pmid">11150164</pub-id><pub-id pub-id-type="doi">10.1021/jm000170m</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vandesompele</surname><given-names>J</given-names></name><name><surname>De Preter</surname><given-names>K</given-names></name><name><surname>Pattyn</surname><given-names>F</given-names></name><name><surname>Poppe</surname><given-names>B</given-names></name><name><surname>Van Roy</surname><given-names>N</given-names></name><name><surname>De Paepe</surname><given-names>A</given-names></name><name><surname>Speleman</surname><given-names>F</given-names></name></person-group><article-title>Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes</article-title><source>Genome Biol</source><year>2002</year><volume>18</volume><fpage>1</fpage><lpage>11</lpage></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dellovade</surname><given-names>TL</given-names></name><name><surname>Merchenthaler</surname><given-names>I</given-names></name></person-group><article-title>Estrogen regulation of neurokinin B gene expression in the mouse arcuate nucleus is mediated by estrogen receptor alpha</article-title><source>Endocrinology</source><year>2004</year><volume>145</volume><fpage>736</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">14592957</pub-id><pub-id pub-id-type="doi">10.1210/en.2003-0894</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>VM</given-names></name><name><surname>Castellano</surname><given-names>JM</given-names></name><name><surname>Fernandez-Fernandez</surname><given-names>R</given-names></name><name><surname>Barreiro</surname><given-names>ML</given-names></name><name><surname>Roa</surname><given-names>J</given-names></name><name><surname>Sanchez-Criado</surname><given-names>JE</given-names></name><name><surname>Aguilar</surname><given-names>E</given-names></name><name><surname>Dieguez</surname><given-names>C</given-names></name><name><surname>Pinilla</surname><given-names>L</given-names></name><name><surname>Tena-Sempere</surname><given-names>M</given-names></name></person-group><article-title>Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide</article-title><source>Endocrinology</source><year>2004</year><volume>145</volume><fpage>4565</fpage><lpage>4574</lpage><pub-id pub-id-type="pmid">15242985</pub-id><pub-id pub-id-type="doi">10.1210/en.2004-0413</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>WC</given-names></name><name><surname>Hillier</surname><given-names>LW</given-names></name><name><surname>Marshall Graves</surname><given-names>JA</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Gr&#x000fc;tzner</surname><given-names>F</given-names></name><name><surname>Belov</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name><name><surname>Clarke</surname><given-names>L</given-names></name><name><surname>Chinwalla</surname><given-names>AT</given-names></name><name><surname>Yang</surname><given-names>SP</given-names></name><name><surname>Heger</surname><given-names>A</given-names></name><name><surname>Locke</surname><given-names>DP</given-names></name><name><surname>Miethke</surname><given-names>P</given-names></name><name><surname>Waters</surname><given-names>PD</given-names></name><name><surname>Veyrunes</surname><given-names>F</given-names></name><name><surname>Fulton</surname><given-names>L</given-names></name><name><surname>Fulton</surname><given-names>B</given-names></name><name><surname>Graves</surname><given-names>T</given-names></name><name><surname>Wallis</surname><given-names>J</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>L&#x000f3;pez-Ot&#x000ed;n</surname><given-names>C</given-names></name><name><surname>Ord&#x000f3;&#x000f1;ez</surname><given-names>GR</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Deakin</surname><given-names>JE</given-names></name><name><surname>Alsop</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>K</given-names></name><name><surname>Kirby</surname><given-names>P</given-names></name><name><surname>Papenfuss</surname><given-names>AT</given-names></name><name><surname>Wakefield</surname><given-names>MJ</given-names></name><name><surname>Olender</surname><given-names>T</given-names></name><name><surname>Lancet</surname><given-names>D</given-names></name><name><surname>Huttley</surname><given-names>GA</given-names></name><name><surname>Smit</surname><given-names>AF</given-names></name><name><surname>Pask</surname><given-names>A</given-names></name><name><surname>Temple-Smith</surname><given-names>P</given-names></name><name><surname>Batzer</surname><given-names>MA</given-names></name><name><surname>Walker</surname><given-names>JA</given-names></name><name><surname>Konkel</surname><given-names>MK</given-names></name><name><surname>Harris</surname><given-names>RS</given-names></name><name><surname>Whittington</surname><given-names>CM</given-names></name><name><surname>Wong</surname><given-names>ES</given-names></name><name><surname>Gemmell</surname><given-names>NJ</given-names></name><name><surname>Buschiazzo</surname><given-names>E</given-names></name><name><surname>Vargas Jentzsch</surname><given-names>IM</given-names></name><name><surname>Merkel</surname><given-names>A</given-names></name><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Zemann</surname><given-names>A</given-names></name><name><surname>Churakov</surname><given-names>G</given-names></name><name><surname>Kriegs</surname><given-names>JO</given-names></name><name><surname>Brosius</surname><given-names>J</given-names></name><name><surname>Murchison</surname><given-names>EP</given-names></name><name><surname>Sachidanandam</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Tsend-Ayush</surname><given-names>E</given-names></name><name><surname>McMillan</surname><given-names>D</given-names></name><name><surname>Attenborough</surname><given-names>R</given-names></name><name><surname>Rens</surname><given-names>W</given-names></name><name><surname>Ferguson-Smith</surname><given-names>M</given-names></name><name><surname>Lef&#x000e8;vre</surname><given-names>CM</given-names></name><name><surname>Sharp</surname><given-names>JA</given-names></name><name><surname>Nicholas</surname><given-names>KR</given-names></name><name><surname>Ray</surname><given-names>DA</given-names></name><name><surname>Kube</surname><given-names>M</given-names></name><name><surname>Reinhardt</surname><given-names>R</given-names></name><name><surname>Pringle</surname><given-names>TH</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>RC</given-names></name><name><surname>Nixon</surname><given-names>B</given-names></name><name><surname>Dacheux</surname><given-names>JL</given-names></name><name><surname>Niwa</surname><given-names>H</given-names></name><name><surname>Sekita</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Stark</surname><given-names>A</given-names></name><name><surname>Kheradpour</surname><given-names>P</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Webber</surname><given-names>C</given-names></name><name><surname>Hardison</surname><given-names>R</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Hallsworth-Pepin</surname><given-names>K</given-names></name><name><surname>Delehaunty</surname><given-names>K</given-names></name><name><surname>Markovic</surname><given-names>C</given-names></name><name><surname>Minx</surname><given-names>P</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Kremitzki</surname><given-names>C</given-names></name><name><surname>Mitreva</surname><given-names>M</given-names></name><name><surname>Glasscock</surname><given-names>J</given-names></name><name><surname>Wylie</surname><given-names>T</given-names></name><name><surname>Wohldmann</surname><given-names>P</given-names></name><name><surname>Thiru</surname><given-names>P</given-names></name><name><surname>Nhan</surname><given-names>MN</given-names></name><name><surname>Pohl</surname><given-names>CS</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Nefedov</surname><given-names>M</given-names></name><name><surname>de Jong</surname><given-names>PJ</given-names></name><name><surname>Renfree</surname><given-names>MB</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name></person-group><article-title>Genome analysis of the platypus reveals unique signatures of evolution</article-title><source>Nature</source><year>2008</year><volume>453</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">18464734</pub-id><pub-id pub-id-type="doi">10.1038/nature06936</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spooren</surname><given-names>W</given-names></name><name><surname>Riemer</surname><given-names>C</given-names></name><name><surname>Meltzer</surname><given-names>H</given-names></name></person-group><article-title>Opinion: NK3 receptor antagonists: the next generation of antipsychotics?</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">16341062</pub-id><pub-id pub-id-type="doi">10.1038/nrd1905</pub-id></citation></ref></ref-list></back></article> 